Key facts
- Three patients died in Chinese gene-editing and cell-therapy clinical trials.
- U.S. Representatives John Moolenaar and Ben Cline have called for increased FDA scrutiny of Chinese clinical trial data.
- The lawmakers expressed concern that U.S. regulatory systems cannot depend on data from opaque and high-risk environments.
- They sent a letter to Acting FDA Commissioner Kyle A. Diamantas on August 20.
U.S. lawmakers are pressing the Food and Drug Administration (FDA) to implement rigorous oversight of clinical trial data originating from China. This call comes after the previously unrevealed deaths of three patients participating in Chinese gene-editing and cell-therapy studies. In a letter dated August 20, Representatives John Moolenaar and Ben Cline urged Acting FDA Commissioner Kyle A. Diamantas to enhance scrutiny, arguing that the U.S. regulatory framework should not rely on data generated within environments perceived as opaque and high-risk. The lawmakers' concerns highlight potential issues with the transparency and safety protocols in certain international biomedical research settings.